{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+duration&page=67",
    "query": {
      "intervention": "Phase duration",
      "page": 67
    },
    "page_size": 10
  },
  "pagination": {
    "page": 67,
    "page_size": 10,
    "total_count": 3756,
    "total_pages": 376,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+duration&page=68&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+duration&page=66&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-04T12:39:00.193Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00077324",
      "title": "Proteomic Profiling in Diagnosing Non-Small Cell Lung Cancer in Patients Who Are Undergoing Lung Resection for Suspicious Stage I Lung Lesions",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "proteomic profiling",
          "type": "GENETIC"
        },
        {
          "name": "surface-enhanced laser desorption/ionization-time of flight mass spectrometry",
          "type": "OTHER"
        },
        {
          "name": "biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2004-02",
      "completion_date": "2011-11",
      "has_results": false,
      "last_update_posted_date": "2016-07-06",
      "last_synced_at": "2026-11-04T12:39:00.193Z",
      "location_count": 72,
      "location_summary": "Birmingham, Alabama • Concord, California • Duarte, California + 53 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00077324"
    },
    {
      "nct_id": "NCT03590054",
      "title": "Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Stage III Cutaneous Melanoma",
        "Stage IV Cutaneous Melanoma",
        "Locally Advanced Melanoma",
        "Locally Advanced Solid Neoplasm",
        "Metastatic Head and Neck Squamous Cell Carcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Melanoma",
        "Metastatic Urothelial Carcinoma",
        "Non-Small Cell Lung Carcinoma",
        "Stage IB Lung Cancer AJCC v7",
        "Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8",
        "Stage III Lung Cancer AJCC v8",
        "Stage III Ureter Cancer AJCC v8",
        "Stage IIIA Lung Cancer AJCC v8",
        "Stage IIIB Lung Cancer AJCC v8",
        "Stage IIIC Lung Cancer AJCC v8",
        "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IV Ureter Cancer AJCC v8",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVB Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Abexinostat",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Rahul Aggarwal",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2018-08-20",
      "completion_date": "2023-11-30",
      "has_results": false,
      "last_update_posted_date": "2024-03-22",
      "last_synced_at": "2026-11-04T12:39:00.193Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03590054"
    },
    {
      "nct_id": "NCT03551886",
      "title": "Automated Assessment Using Facial Coding",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Substance Use Disorders"
      ],
      "interventions": [
        {
          "name": "Advanced Emotion App",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Basic Emotion App",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Treatment Innovations",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "26 Years",
        "sex": "ALL",
        "summary": "18 Years to 26 Years"
      },
      "enrollment_count": 153,
      "start_date": "2020-10-01",
      "completion_date": "2022-03-01",
      "has_results": false,
      "last_update_posted_date": "2022-04-27",
      "last_synced_at": "2026-11-04T12:39:00.193Z",
      "location_count": 1,
      "location_summary": "Newton, Massachusetts",
      "locations": [
        {
          "city": "Newton",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03551886"
    },
    {
      "nct_id": "NCT01468454",
      "title": "Phase II Safety and Efficacy Study of 18FDOPA PET-CT in Children With Hyperinsulinemic Hypoglycemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Congenital Hyperinsulinism (CHI)",
        "Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)"
      ],
      "interventions": [
        {
          "name": "18 F-DOPA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 130,
      "start_date": "2009-01",
      "completion_date": "2018-02",
      "has_results": true,
      "last_update_posted_date": "2022-10-13",
      "last_synced_at": "2026-11-04T12:39:00.193Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01468454"
    },
    {
      "nct_id": "NCT03831880",
      "title": "Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Growth Hormone Deficiency"
      ],
      "interventions": [
        {
          "name": "Genotropin",
          "type": "DRUG"
        },
        {
          "name": "somatrogon",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "3 Years to 17 Years"
      },
      "enrollment_count": 87,
      "start_date": "2019-02-07",
      "completion_date": "2020-08-28",
      "has_results": true,
      "last_update_posted_date": "2021-10-14",
      "last_synced_at": "2026-11-04T12:39:00.193Z",
      "location_count": 18,
      "location_summary": "Sacramento, California • Aurora, Colorado • Centennial, Colorado + 11 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Greenwood Village",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03831880"
    },
    {
      "nct_id": "NCT03990961",
      "title": "Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large B Cell Lymphoma",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2019-09-04",
      "completion_date": "2024-04-01",
      "has_results": true,
      "last_update_posted_date": "2026-02-20",
      "last_synced_at": "2026-11-04T12:39:00.193Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03990961"
    },
    {
      "nct_id": "NCT05875129",
      "title": "Device Feasibility and Acceptability to Improve Insomnia in Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cancer",
        "Insomnia Chronic"
      ],
      "interventions": [
        {
          "name": "VAVA prototype",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Medstar Health Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "18 Years to 39 Years"
      },
      "enrollment_count": 15,
      "start_date": "2022-07-20",
      "completion_date": "2023-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-09-12",
      "last_synced_at": "2026-11-04T12:39:00.193Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05875129"
    },
    {
      "nct_id": "NCT05568550",
      "title": "Pembro With Radiation With or Without Olaparib",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Androgen Deprivation Therapy",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Zin W Myint",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 64,
      "start_date": "2023-07-27",
      "completion_date": "2029-07-02",
      "has_results": false,
      "last_update_posted_date": "2026-07-14",
      "last_synced_at": "2026-11-04T12:39:00.193Z",
      "location_count": 2,
      "location_summary": "Lexington, Kentucky • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05568550"
    },
    {
      "nct_id": "NCT06013579",
      "title": "Effect of High-Intensity Exercise to Attenuate Cognitive Function Limitations and Train Exercise Habits in Older People Living With HIV",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections",
        "Cognitive Impairment"
      ],
      "interventions": [
        {
          "name": "Phase 1 Gym Exercise HIIT",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Phase 1 Gym Exercise CME",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Phase 2 Home Exercise Coaching Text Messages",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Phase 2 Home Exercise Control Text Messages",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "50 Years to 80 Years"
      },
      "enrollment_count": 110,
      "start_date": "2023-08-01",
      "completion_date": "2028-03",
      "has_results": false,
      "last_update_posted_date": "2025-12-08",
      "last_synced_at": "2026-11-04T12:39:00.193Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Aurora, Colorado • Seattle, Washington",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06013579"
    },
    {
      "nct_id": "NCT03276559",
      "title": "Enhancing & Mobilizing the POtential for Wellness & Emotional Resilience Among Surrogate Decision-Makers of ICU Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Critical Illness",
        "Communication Disabilities"
      ],
      "interventions": [
        {
          "name": "EMPOWER",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Enhanced Usual Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2017-07-12",
      "completion_date": "2023-05-22",
      "has_results": true,
      "last_update_posted_date": "2024-08-20",
      "last_synced_at": "2026-11-04T12:39:00.193Z",
      "location_count": 3,
      "location_summary": "Flushing, New York • New York, New York",
      "locations": [
        {
          "city": "Flushing",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03276559"
    }
  ]
}